

FOI 3788

9<sup>th</sup> June 2026

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Please note for both questions, if a patient has received multiple injection/implants in the time period specified of January to April 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two.**

**Question 1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2026:**

- **Aflibercept - Eylea**
- **Aflibercept - Biosimilar**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab - including all Biosimilars**

**Response:**

- **Aflibercept – Eylea 0**
- **Aflibercept – Biosimilar 0**
- **Bevacizumab 0**
- **Brolucizumab 0**
- **Dexamethasone 0**
- **Faricimab 0**
- **Fluocinolone acetonide 0**
- **Ranibizumab - including all Biosimilars 0**

**Question 2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2026:**

- **Aflibercept - Eylea**
- **Aflibercept - Biosimilar**
- **Bevacizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab - including all Biosimilars**

| Treatment                               | Eye Condition                        |                               |                              |                              |
|-----------------------------------------|--------------------------------------|-------------------------------|------------------------------|------------------------------|
|                                         | Wet Age-Related Macular Degeneration | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) | Non-infectious Uveitis (NIU) |
| Aflibercept - Eylea                     |                                      |                               |                              | n/a                          |
| Aflibercept - Biosimilar                |                                      |                               |                              | n/a                          |
| Bevacizumab                             |                                      |                               |                              | n/a                          |
| Dexamethasone                           |                                      |                               |                              |                              |
| Faricimab                               |                                      |                               |                              | n/a                          |
| Fluocinolone acetonide                  |                                      |                               |                              |                              |
| Ranibizumab - including all Biosimilars |                                      |                               |                              | n/a                          |

**Response:**

- **Aflibercept – Eylea 0**
- **Aflibercept – Biosimilar 0**
- **Bevacizumab 0**
- **Dexamethasone 0**

- Faricimab 0
- Fluocinolone acetonide 0
- Ranibizumab - including all Biosimilars 0

| Treatment                               | Eye Condition                        |                               |                              |                              |
|-----------------------------------------|--------------------------------------|-------------------------------|------------------------------|------------------------------|
|                                         | Wet Age-Related Macular Degeneration | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) | Non-infectious Uveitis (NIU) |
| Aflibercept - Eylea                     | 0                                    | 0                             | 0                            | n/a                          |
| Aflibercept - Biosimilar                | 0                                    | 0                             | 0                            | n/a                          |
| Bevacizumab                             | 0                                    | 0                             | 0                            | n/a                          |
| Dexamethasone                           | 0                                    | 0                             | 0                            |                              |
| Faricimab                               | 0                                    | 0                             | 0                            | n/a                          |
| Fluocinolone acetonide                  | 0                                    | 0                             | 0                            |                              |
| Ranibizumab - including all Biosimilars | 0                                    | 0                             | 0                            | n/a                          |

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)